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Pigeon paramyxovirus type 1 from a 
fatal human case induces pneumonia 
in experimentally infected cynomolgus 
macaques (Macaca fascicularis)
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Abstract 
Although avian paramyxovirus type 1 is known to cause mild transient conjunctivitis in human beings, there are two 
recent reports of fatal respiratory disease in immunocompromised human patients infected with the pigeon lineage 
of the virus (PPMV-1). In order to evaluate the potential of PPMV-1 to cause respiratory tract disease, we inoculated a 
PPMV-1 isolate (hPPMV-1/Netherlands/579/2003) from an immunocompromised human patient into three healthy 
cynomolgus macaques (Macaca fascicularis) and examined them by clinical, virological, and pathological assays. In 
all three macaques, PPMV-1 replication was restricted to the respiratory tract and caused pulmonary consolidation 
affecting up to 30% of the lung surface. Both alveolar and bronchiolar epithelial cells expressed viral antigen, which 
co-localized with areas of diffuse alveolar damage. The results of this study demonstrate that PPMV-1 is a primary 
respiratory pathogen in cynomolgus macaques, and support the conclusion that PPMV-1 may cause fatal respiratory 
disease in immunocompromised human patients.
© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Newcastle disease virus, or avian paramyxovirus type 1 
(APMV-1), is classified in the genus Avulavirus, family 
Paramyxoviridae [1]. Genetic and antigenic analyses have 
demonstrated that APMV-1 strains cluster in 10 different 
genotypes, with different sublineages [2]. Based on their 
difference in reactivity in hemagglutination assays, and 
their host specificity for columbiform species, all pigeon 
paramyxoviruses (PPMV-1) cluster in lineage VIb/1 of 
genotype VI APMV-1 strains [2–5].
APMV-1 infection is known to cause mild disease in 
human beings. Most commonly, human infection is asso-
ciated with conjunctivitis, which resolves within 1 week. 
Less often, it is associated with transient fever or chills 
[6–9]. So far, only two fatal cases of human infection 
have been reported, one in the USA [10] and the other 
in the Netherlands [11] (unpublished observations). 
Both patients had an immunosuppressive condition as 
a comorbidity and developed severe pneumonia. Both 
virus isolates from the patients were typed as PPMV-1. 
PPMV-1 was first detected in Southeastern Europe in 
the 1980s and became established in pigeon populations 
across Europe. From there, PPMV-1 has spread and con-
tinues to spread worldwide. PPMV-1 is now established 
in both domestic and wild pigeons and doves in Europe 
and North America, from where it can often spread to 
poultry, with outbreaks reported [2, 12].
Strains of APMV-1 and PPMV-1 can be categorized 
into three different groups based on the severity of dis-
ease they cause in birds: lentogenic (avirulent), meso-
genic (intermediate virulent) and velogenic (virulent). 
These differences in virulence can be explained mostly by 
differences in the cleavage site of the fusion (F) protein, 
which is synthesized in an inactive form (F0) and needs to 
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be proteolytically cleaved by host cellular proteases into 
active F1 and F2 forms in order to become functional. 
Activation of the F0 protein will result in fusogenic activ-
ity promoting virus-to-cell fusion and cell-to-cell fusion. 
Lentogenic viruses have a monobasic cleavage site, which 
can only be cleaved by trypsin-like proteases found in the 
respiratory and digestive tracts of birds. More virulent 
strains have a polybasic cleavage site, which can also be 
cleaved by furin-like proteases, found more abundantly 
in most organs and explaining why virulent strains can 
replicate systemically in birds [13].
APMV-1 strains have been tested in different animal 
models to evaluate their virulence for mammals. Inocu-
lation of lentogenic, mesogenic, and velogenic strains 
of APMV-1 induced conjunctivitis in rhesus macaques 
(Macaca mulatta) and rabbits, but only after mild 
mechanical abrasion of the conjunctival epithelium [14]. 
Intranasal combined with intratracheal inoculation of 
a mesogenic strain of APMV-1 (Beaudette C) into Afri-
can green monkeys (Cercopithecus aethiops) resulted in a 
low level of replication at scattered locations in the lung, 
without overt disease signs: pathological changes were 
not evaluated [15]. Intranasal inoculation of a lentogenic 
strain of APMV-1 (La Sota) into BALB/c mice [16] or 
Syrian golden hamsters [17] resulted in body weight loss 
and, at 3  days post inoculation (dpi), necrotizing bron-
cho-interstitial pneumonia associated with virus antigen 
expression in bronchial epithelium. However, the viru-
lence of PPMV-1 in laboratory mammals, as a model for 
human disease, has not been evaluated.
We used the PPMV-1 isolate from a fatal human case 
(hPPMV-1/Netherlands/579/2003) to investigate the 
potential of this virus to cause respiratory tract disease 
in a non-human primate. To this end, three cynomol-
gus macaques (Macaca fascicularis) were inoculated 
and pathological, immunohistochemical and virological 
analyses were performed at 3 dpi. We demonstrate that 
PPMV-1 can cause severe virus-associated pneumonia in 
a non-human primate model.
Materials and methods
Virus preparation
The hPPMV-1/Netherlands/579/2003 isolate was 
obtained from an adult female patient from the Nether-
lands with multiple myeloma, who died from respiratory 
failure after receiving allogenic bone marrow transplan-
tation and immunosuppressive treatment [11] (unpub-
lished observations). The virus isolate was passaged 
twice on human rhabdomyosarcoma cells and once on 
Vero cells. Prior to inoculation, the virus isolate was cul-
tured in 10-day-old specific-pathogen-free embryonated 
chicken eggs using standard techniques, and harvested at 
2 dpi. The virus stock was titrated by end-point dilution 
assay in Vero clone 118 cells. To read out infection, cells 
were stained with chicken polyclonal anti-APMV-1 anti-
body and rabbit FITC-labeled anti-chicken IgG anti-
body (1:2000 and 1:1000 dilution respectively; both from 
Abcam, Cambridge, UK) 72  h after inoculation. Viral 
titers were calculated using the method of Reed and 
Muench [18]. The infectious virus titer of this stock was 
5 × 108 median tissue culture infective dose  (TCID50) per 
mL.
Experimental protocol
Three male cynomolgus macaques, 3.5  years old, were 
colony bred and had been maintained in group housing, 
where they were screened annually—and tested nega-
tive—for the following infections: simian virus 40, poly-
omavirus, Mycobacterium tuberculosis, measles virus, 
mumps virus, simian immunodeficiency virus, sim-
ian retrovirus type D, and simian T cell leukemia virus. 
Prior to infection, they were examined clinically and 
determined as healthy by a registered veterinarian. One 
month before the start of the experiment, a Data Stor-
age Tag centi-Temperature probe (Star-Oddi, Brussels, 
Belgium) was implanted intraperitoneally, set to register 
temperature every 10  min. One week before inocula-
tion, the macaques were placed together in a negatively 
pressurized, HEPA-filtered isolator cage. They were pro-
vided with commercial food pellets and water ad libitum. 
The macaques were inoculated with 1.0 × 108  TCID50 of 
hPPMV-1/Netherlands/579/2003, which was suspended 
in 4.5  mL of phosphate-buffered saline (PBS). Approxi-
mately 3 mL was applied intratracheally by use of a cath-
eter, 0.5  mL in each nare, and 0.25  mL on each of the 
conjunctivae. The macaques were observed daily for the 
occurrence of malaise, coughing, exudate from the eyes 
or nose, forced respiration, and any other signs of illness. 
The macaques were euthanized at 3 dpi by exsanguina-
tion under ketamine and medetomidine hydrochloride 
anesthesia. Just before infection and daily until euthana-
sia, the macaques were anesthetized with ketamine and 
medetomidine hydrochloride, and pharyngeal, nasal, 
ocular, and rectal swabs were collected in 1 mL transport 
medium [19] and stored at −70 °C until quantitative RT-
PCR (qRT-PCR) and/or virus isolation. In addition, 4 mL 
blood was taken from an inguinal vein at each of these 
time points and collected in Vacuette Z Serum Sep Clot 
Activator tubes (Greiner Bio One, Alphen aan den Rijn, 
The Netherlands).
Clinical biochemistry
Clotted blood samples were centrifuged and 100  µL 
separated serum was assayed with Piccolo BioChemistry 
Panel Plus Reagent Discs (Abaxis, Darmstadt, Germany), 
which were processed using a Piccolo Xpress chemistry 
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analyzer (Abaxis) following the manufacturer’s instruc-
tions. Measurements were obtained for glucose, blood 
urea nitrogen, creatinine, calcium, albumin, total protein, 
alanine aminotransferase, aspartate aminotransferase, 
alkaline phosphatase, γ-glutamyl transpeptidase, amyl-
ase and C-reactive protein. Reference values (if indicated) 
were obtained from the supplemental data of a publica-
tion by Xie et al. [20].
Autopsy and tissue sampling
Autopsies were carried out according to a standard pro-
tocol. Organs were examined for lesions and sampled 
for laboratory analyses. For histopathology and immu-
nohistochemistry, samples of adrenal gland, brain stem, 
cerebellum, cerebrum, conjunctiva, ethmoid bone, eye, 
eyelid, heart (left and right ventricle), kidney, large intes-
tine, lung (left and right; upper, middle and lower lobes), 
liver, mesenteric lymph nodes, nasal conchae, pancreas, 
small intestine, spleen, tonsil and tracheo-bronchial 
lymph nodes were collected in 10% neutral-buffered for-
malin (lungs after inflation with formalin) and allowed 
to fix for 1 week. For qRT-PCR, broncho-alveolar lavage 
(BAL) was performed by direct infusion of PBS into the 
right main bronchus. Recovered BAL fluid was centri-
fuged and the cellular pellet resuspended in TRIzol and 
stored at −80 °C until further analysis. In addition, sam-
ples of adrenal gland, brain, cerebrospinal fluid, conjunc-
tivae, heart, kidney, mesenteric lymph nodes, lung (right 
upper and lower lobes), large intestine, liver, nasal con-
chae, nasal septum, pancreas, primary bronchus, small 
intestine, spleen, trachea, and tracheo-bronchial lymph 
nodes were collected in RNAlater (Life Technologies, 
Bleiswijk, The Netherlands) and stored at −80  °C until 
further analysis. For virus isolation, samples from the 
same tissues as for qRT-PCR were stored without addi-
tives at −80 °C until further analysis.
Histopathology
Samples for histopathological analysis were embedded in 
paraffin, sectioned at 3 µm, and stained with hematoxy-
lin and eosin (H&E) for examination by light microscopy. 
Tissue sections of a clinically healthy juvenile cynomol-
gus macaque that had not been infected with PPMV-1 
were used as a negative control.
Immunohistochemistry
Formalin-fixed, paraffin-embedded, 3-µm-thick sections 
of the same tissues examined histopathologically were 
stained using an immunoperoxidase method. Tissue sec-
tions were mounted on coated slides (Klinipath, Duiven, 
The Netherlands), deparaffinized and rehydrated. Endog-
enous peroxidase was blocked by incubating sections in 
3%  H2O2 in PBS for 10  min at room temperature (RT). 
Antigen was retrieved by Tris–EDTA buffer (pH 9) for 
15  min. Sections were subsequently washed with PBS 
containing 0.05% Tween 20 (Fluka, Chemie AG, Buchs, 
Switzerland) and incubated in PBS with 0.1% BSA 
(Aurion, Wageningen, The Netherlands) for 10 min at RT. 
After this, sections were incubated in PBS with 0.1% BSA 
with a monoclonal mouse antibody IgG2a to APMV-1 
(dilution 1:100, MAb 6H12, specific to ribonucleopro-
tein; La Sota strain, Hytest Ltd, Turku, Finland) or with 
a negative control isotype mouse monoclonal antibody 
(dilution 1:100, MAb 003, R&D System, Minneapolis, 
USA) for 1  h at RT. After washing, sections were incu-
bated with goat anti-mouse antibody (dilution 1:400, 
Table 1 Temporal course in clinical chemical values in the plasma of cynomolgus macaques inoculated with hPPMV-1/
Netherlands/579/2003
na: not available.
Analyte Unit Normal range Macaque #1 Macaque #2 Macaque #3
D0 D1 D2 D3 D0 D1 D2 D3 D0 D1 D2 D3
Glucose mmol/L 2.16–7.92 4.6 5.7 3.5 4.5 5.5 6.8 5.8 7.9 4.9 6.1 4.8 7.2
Blood urea nitrogen mmol/L 4.36–9.28 4.9 7.6 5.6 5.2 5.1 5.9 5.3 5.8 5.8 7.2 6.7 6.6
Creatinine µmol/L 30.57–72.37 57 60 49 70 59 93 65 64 49 68 53 51
Uric acid µmol/L na <18 <18 <18 <18 <18 <18 <18 <18 <18 <18 <18 <18
Calcium mmol/L 2.32–2.96 2.54 2.43 2.55 2.39 2.53 2.43 2.51 2.38 2.53 2.47 2.58 2.47
Albumin g/L 28.31–50.79 27 23 25 24 31 30 29 28 32 29 31 31
Total protein g/L 61.91–88.11 65 62 61 61 65 66 64 63 67 64 67 66
Alanine aminotransferase U/L 2.95–87.03 58 60 77 82 134 103 87 84 42 52 56 70
Aspartate aminotransferase U/L 24.30–69.90 51 62 82 148 166 61 90 127 43 56 80 106
Alkaline phosphatase U/L 121.22–727.22 175 159 158 149 335 307 310 322 374 334 334 318
Gamma glutamyltransferase U/L 14.61–62.53 75 62 66 63 24 25 25 24 52 46 50 47
Amylase U/L na 459 321 661 471 268 173 262 217 378 308 378 347
C-reactive protein mg/L na <5 10.1 <5 <5 <5 98.4 <5 <5 <5 7 <5 <5
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Southern Biotech, Birmingham, AL, USA) labeled with 
horseradish peroxidase (HRP) for 1 h at RT. HRP activ-
ity was revealed by incubating the sections in 3-amino-
9-ethylcarbazole (Sigma Chemical Co., St. Louis, USA) in 
N,N-dimethylformamide (Sigma Chemical Co.) solution 
for 10 min at RT, resulting in a red precipitate. Sections 
were counterstained with hematoxylin. Brain tissue sec-
tions from a cormorant (Phalacrocorax auritus) known 
to be infected with APMV-1 were used as a positive 
control. Tissue sections of a clinically healthy juvenile 
cynomolgus macaque that had not been infected with 
PPMV-1 were used as a negative control.
RNA isolation and qRT‑PCR assay
BAL samples stored in TRIzol were processed according 
to the manufacturer’s instructions to isolate RNA. Tis-
sue samples stored in RNAlater were weighed, thawed, 
transferred to tubes containing a quarter-inch-diam-
eter ceramic sphere in virus transport medium, and 
homogenized using a FastPrep 24 tissue homogenizer 
(MP Biomedicals, Eindhoven, The Netherlands). The 
homogenates were centrifuged, and the cleared superna-
tants were used for RNA isolation. 200 µL of the cleared 
supernatant of tissue samples, as well as 200 µL of other 
samples (transport medium of swabs, plasma) were 
Figure 1 Gross pathology of experimental hPPMV-1/Netherlands/579/2003 infection in cynomolgus macaques. A–C Overview of the 
ventral aspect of the lungs. D, E Close-up of the right lower lung lobe. F Close-up of the right upper and middle lung lobes. There is a locally exten-
sive area of consolidation in the right lower lung lobe of macaques #1 (A, D) and #2 (B, E), likely due to a substantial part of the inoculum flowing 
into this lobe. There are multiple areas of consolidation (arrows) in the right upper and middle lung lobes of macaque #3 (C, F).
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combined with 300 µL lysis buffer of the Total Nucleic 
Acid Isolation kit (Roche, Woerden, The Netherlands) 
and RNA was isolated in a volume of 50 µL using a 
MagNA Pure LC machine (Roche) following the manu-
facturer’s instructions.
NDV-specific qRT-PCR was performed on 5 µL (TRI-
zol samples) or 19.5 µL (MagNA Pure samples) RNA in 
an ABI PRISM 7000 Sequence Detection System using 
TaqMan Fast Virus 1-Step Master Mix (both from Life 
Technologies) in a total volume of 30 µL, using primers 
as described by Wise et al. [21]. The RT step was 5 min at 
50 °C, followed by 95 °C for 20 s. Cycling consisted of 45 
cycles of 3 s denaturation at 95 °C, 5 s annealing at 54 °C 
and 31 s extension at 60 °C.
Virus isolation
200 µL transport medium from collected swabs or 200 
µL supernatant from homogenized tissue samples was 
injected in duplicate into 10-day-old specific-pathogen-
free embryonated chicken eggs. After 2  days, allantoic 
fluid was harvested and tested for presence of virus by 
hemagglutination assay.
Results
Clinical findings of experimentally infected macaques
The body temperature of macaque #2 increased to 
39.5  °C at 0.5 dpi, compared to 38.5  °C for macaque #1 
and 38.0 °C for macaque #3 at that time point. Otherwise, 
no clinical signs were seen. Clinical chemical changes in 
the plasma were limited to creatinine and C-reactive pro-
tein (Table 1). The creatinine concentration of macaque 
#2 was slightly elevated at 1 dpi, but returned to normal 
concentrations at 2 and 3 dpi. The creatinine concentra-
tions of the other macaques remained within the nor-
mal range. The C-reactive protein concentrations in all 
macaques were increased at 1 dpi, and returned below 
the level of detection at 2 and 3 dpi.
Gross pathology
All three macaques had locally extensive or multifo-
cal pulmonary lesions, which were red–purple, slightly 
raised, and firmer than normal (Figure 1). The estimated 
volume of affected lung tissue differed per macaque: 
30% (macaque #1), 25% (macaque #2), and 1% (macaque 
#3). The only gross lesions outside the respiratory tract 
Figure 2 Pulmonary histopathology and immunohistochemistry of experimental hPPMV-1/Netherlands/579/2003-infection in 
cynomolgus macaques. A Pulmonary section of macaque #1. Diffuse alveolar damage. There is edema fluid and inflammatory cells in the alveolar 
lumina (H&E. Original magnification ×2). B Pulmonary section of macaque #1. Diffuse alveolar damage. There are macrophages, lymphocytes, neu-
trophils, and rare eosinophils, mixed with fibrin strands, in the alveolar lumen (H&E. Original magnification ×40). C Pulmonary section of macaque 
#1. Diffuse alveolar damage. In addition to inflammatory cells, there is abundant edema fluid in the alveolar lumen (H&E. Original magnification 
×40). D Pulmonary section of macaque #1. Diffuse alveolar damage. Hyaline membranes lining the alveolar walls (H&E. Original magnification ×20). 
E Pulmonary section of macaque #1. Diffuse alveolar damage. There is loss of epithelial cells from the bronchiolar wall (H&E. Original magnification 
×40). F Pulmonary section of macaque #2. Diffuse alveolar damage. Hypertrophy of type II pneumocytes lining the alveolar wall (H&E. Original 
magnification ×40). G Pulmonary section of macaque #2. Diffuse alveolar damage. Expression of PPMV-1 in epithelial cells of the alveoli (immun-
operoxidase stain for PPMV-1. Original magnification ×40). H Pulmonary section of macaque #1. Diffuse alveolar damage. Expression of PPMV-1 in 
type I pneumocytes and type II pneumocytes (immunoperoxidase stain for PPMV-1. Original magnification ×100).
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were in lymphoid organs. All three macaques had 
enlarged tracheo-bronchial lymph nodes and promi-
nent white pulp of the spleen, while macaque #1 also 
had enlarged tonsils and mandibular lymph nodes, and 
multiple red areas in mesenteric and pancreatic lymph 
nodes.
Histopathology
In the lung, all three macaques had multiple or coalesc-
ing foci of inflammation and necrosis that centered on 
the bronchioles (Figure 2). In these foci, the alveolar and 
bronchiolar lumina were filled with macrophages, lym-
phocytes, neutrophils, and rare eosinophils, mixed with 
edema fluid, fibrin, erythrocytes, and cellular debris. 
Alveolar and bronchiolar epithelia had evidence of both 
necrosis (denuded basement membranes and attenuated 
bronchiolar epithelial cells) and regeneration (type II 
pneumocyte hypertrophy and hyperplasia). The alveolar 
and bronchiolar walls were moderately thickened by the 
presence of mononuclear cells, neutrophils, and edema 
fluid. Some alveolar walls were lined by hyaline mem-
branes. The bronchi were only mildly affected. There was 
moderate accumulation of lymphocytes around branches 
of both pulmonary arteries and pulmonary veins, and 
mild infiltration of mononuclear cells and neutrophils in 
pulmonary vein walls. The pleura overlying the inflam-
matory foci was infiltrated with mononuclear cells, neu-
trophils, and eosinophils.
The lymph nodes and spleen had benign lymphoid 
hyperplasia, characterized by an increased number of 
lymphocytes and expansion of germinal centers. In addi-
tion, the medullary sinuses in the pancreatic and mes-
enteric lymph nodes of macaque #1 contained many 
erythrocytes; furthermore, the colon of this macaque 
had multiple small hemorrhages in the lamina propria. 
Macaques #1 and 2 had a mild superficial tonsillitis, 
characterized by the presence of neutrophils and bacte-
rial colonies in the lumen and epithelium of the tonsillar 
crypt. Macaque #3 had a mild superficial conjunctivitis, 
characterized by the presence of neutrophils, lympho-
cytes, plasma cells, and expansile lymphoid follicles in 
the subconjunctival connective tissue, and migration 
of neutrophils through the conjunctiva into the lumen 
(Figure 3).
Immunohistochemistry
Expression of PPMV-1 was visible as red–brown granu-
lar cytoplasmic staining in alveolar and bronchiolar 
epithelial cells in affected areas of the lung in all three 
macaques (Figure  2). Neither unaffected areas of the 
respiratory tract nor extra-respiratory organs showed 
PPMV-1 expression. PPMV-1 expression was present in 
the positive control tissue and absent in the isotype con-
trol and negative control tissues.
qRT‑PCR and virus isolation
By qRT-PCR, the highest levels of PPMV-1 RNA were 
detected in eye, nose, and throat swabs of all three 
macaques at 1 dpi (Figure  4). The amount of RNA 
declined on subsequent days, but RNA was still detect-
able at 3 dpi in 1 (nose swab) or 2 out of three macaques 
(eye and throat swabs). Virus isolation conducted with 
RNA-positive swabs demonstrated the presence of infec-
tious virus only at 1 dpi in the throat swabs of macaques 
#2 (titer: 1.0  ×  101  TCID50/mL) and #3 (2.3  ×  102 
 TCID50/mL) and the eye swab of macaque #3 (7.4 × 102 
 TCID50/mL).
At autopsy, PPMV-1 was detected by qRT-PCR and 
virus isolation in the lung of all three macaques (Table 2). 
PPMV-1 also was detected by qRT-PCR but not by virus 
isolation in other respiratory tract tissues: nasal turbi-
nate, trachea and bronchus. Except for tracheo-bronchial 
Figure 3 Conjunctival histopathology of experimental 
hPPMV-1/Netherlands/579/2003 infection in cynomolgus 
macaques. A Conjunctival section of macaque #3. Conjunctivitis. 
There are neutrophils in the subconjunctival connective tissue and 
conjunctiva (H&E. Original magnification ×20). B Conjunctival section 
of macaque #3. Conjunctivitis. Enlarged lymphoid follicles in the sub-
conjunctival connective tissue (H&E. Original magnification ×2).
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lymph node, which was positive by qRT-PCR but not by 
virus isolation, all extra-respiratory organs were negative 
for PPMV-1 by qRT-PCR and virus isolation.
Discussion
This experimental infection shows that a PPMV-1 iso-
late from a fatal human case can cause severe pneumonia 
in a non-human primate model. Histological lesions in 
PPMV-1-infected macaques consisted of diffuse alveolar 
damage, affecting up to 30% of the lungs. The co-localiza-
tion of these lesions with specific expression of PPMV-1 
antigen, together with the re-isolation of PPMV-1 from 
lung samples at autopsy, support our conclusion that 
PPMV-1 infection was the cause of pneumonia.
These findings largely correspond with the presentation 
of infection with PPMV-1 in two human fatal cases from 
New York [10] and The Netherlands [11] (unpublished 
observations). Both human patients also developed 
pneumonia. The histopathological characterization of the 
pneumonia in our macaques was nearly identical to that 
in the New York and Dutch patients. The cell tropism also 
appeared to be the same in our macaques (pneumocytes 
and bronchioloar epithelial cells) and the New York and 
Dutch patients, where cells expressing PPMV-1 antigen 
resembled sloughed pneumocytes. This sloughing may 
have been due to a prolonged interval between death and 
autopsy; it also would preclude definite differentiation 
between alveoli and adjacent bronchioles as the source of 
the sloughed epithelial cells. While it was suggested that 
the New York and Dutch patients had systemic infection 
based on PPMV-1-positive urine and stool samples (New 
York patient) and PPMV-1-positive extra-respiratory tis-
sues (Dutch patient), we did not detect PPMV-1 in any 
extra-respiratory tissues—including kidney, small and 
large intestines, pancreas and liver—of our macaques, 
either by qRT-PCR, virus isolation, or immunohisto-
chemistry. However, it cannot be excluded that under 
conditions of immunosuppression, the virus would be 
able to spread systemically in macaques.
The results of this study, together with those of two 
fatal human cases of PPMV-1 infection, indicate that 
some PPMV-1 can cause severe pneumonia in people 
and macaques under certain conditions. These condi-
tions include immunosuppression, intratracheal route 
of infection, and high viral dose. It remains to be deter-
mined whether PPMV-1, and particularly these isolates 
from fatal human cases, are more virulent for people 
than other APMV-1 strains. APMV-1 is able to selec-
tively replicate in cancer cells and therefore is a potential 
therapeutic agent in cancer therapy. During application 
of different APMV-1 strains by different routes—locally, 
subcutaneously, intravenously, by inhalation—in clini-
cal trials involving thousands of people, severe adverse 
effects have not been recorded [22]. Also, preclinical 
studies employing APMV-1 as a vaccine vector by differ-
ent routes, or employing APMV-1 as a high-dose intra-
venous cytolytic agent, all demonstrated that APMV-1 
Figure 4 Detection of hPPMV-1/Netherlands/579/2003 by 
qRT-PCR in experimentally infected cynomolgus macaques. 
Circle: macaque #1, square: macaque #2, triangle: macaque #3.
Page 8 of 9Kuiken et al. Vet Res  (2017) 48:80 
is not pathogenic in non-human primates [15, 23–28]. 
The virulence of PPMV-1—a pigeon-specific lineage of 
APMV-1—for humans and macaques suggests that the 
strain used should be carefully selected.
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